Predicta Biosciences has raised $23.4M in an oversubscribed Series A led by Engine Ventures to scale its diagnostic platform for blood cancers and autoimmune diseases.

Oct 01, 2025•3 days ago

Amount Raised

$23.4 Million

Round Type

series a

CambridgeBiotechnologyHealth Care

Investors

Myeloma Solutions FundBinney Street Capital Of Dana Farber Cancer InstituteAcs Bright EdgeMass General Brigham VenturesLightchain CapitalIllumina VenturesEngine Ventures

Description

Predicta Biosciences announced it has raised $23.4 million in a Series A funding round led by Engine Ventures. Additional investors include Illumina Ventures and Mass General Brigham Ventures. The funds will enhance Predicta's lab infrastructure and advance its GenoPredicta test. Brian McKernan has been appointed as CEO to drive the company's clinical impact.

Company Information

Company

Predicta Biosciences

Location

Cambridge, Massachusetts, United States

About

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends